Guillaume Pfefer, Senda Biosciences CEO

Two years post-merg­er, Flag­ship’s Sen­da re­fines pipeline and re­plen­ish­es the bank 

Sen­da Bio­sciences will look a lit­tle dif­fer­ent than it did two years ago when Flag­ship Pi­o­neer­ing un­wrapped the bow on the ven­ture, a merg­er of Sen­da and Kin­tai Ther­a­peu­tics.

Orig­i­nal­ly home to six pre­clin­i­cal pro­grams with am­bi­tions for treat­ing mul­ti­ple scle­ro­sis, Parkin­son’s, col­orec­tal can­cer, chron­ic kid­ney dis­ease, obe­si­ty and oth­er dis­eases, the start­up is fine-tun­ing its path and will soon present a clear­er scope of its fu­ture.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.